Polaprezinc exerts a salutary effect on impaired healing of acute gastric lesions in diabetic rats
Laboratory studyOther animalsWith zinc (as polaprezinc)
This study tested carnosine together with zinc (as polaprezinc). Its results cannot be assigned to carnosine alone. More combination studies.
- Design
- Laboratory study
- Dose used in the study
- Polaprezinc 3 to 30 mg/kg, or zinc sulfate and L-carnosine alone or combined, orally twice daily
- Duration
- 4 days after HCl injury
- What was measured
- Healing of HCl-induced gastric lesions over 10 days in streptozotocin-diabetic rats, blood glucose, acid secretion and mucosal IGF-I mRNA, with insulin, polaprezinc, its components or recombinant IGF-I.
What the authors reported
Diabetes did not change lesion formation but markedly delayed healing; insulin corrected this. Polaprezinc above 10 mg/kg significantly reversed the healing delay without affecting glucose or acid secretion; zinc sulfate alone or with L-carnosine showed similar trends but L-carnosine alone did not. Mucosal IGF-I mRNA was reduced in diabetic rats and partly restored by insulin and polaprezinc, and recombinant IGF-I also promoted healing.
Limits of this study
Rat model; the carnosine component alone was ineffective, so the effect is attributed to zinc. One author is from the manufacturer (Zeria). Rodents lack serum carnosinase, so oral results do not carry over to people. Abstract only.
Source
PubMed 10877238 · doi:10.1023/a:1005566406257
Entry checked against PubMed abstract (E-utilities) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.